Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects
Summary
Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic acting on the serotonin 5-HT2A receptor. LSD is used recreationally and in psychiatric research. First studies suggest efficacy in psychiatric disorders, such as depression and anxiety. SSRIs like paroxetine are first-line treatments for depression and anxiety disorders. Paroxetine acts as a serotonin transporter (SERT) inhibitor. However, the link between this mechanism and its positive effects on mood remains to be established. Several studies suggest a possible downregulation of postsynaptic serotonin (5-HT) receptors such as the 5-HT2A receptor. The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to LSD.
Timeline
- Start
- 2022-10-24
- Primary completion
- 2024-02-20
- Completion
- 2024-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lysergic Acid Diethylamide | Other / unclassified | 0.1 mg | Oral |
| Comparator | Paroxetine | Small molecule | 20 mg | Oral |
Indications
No indication recorded.